RCEL (AVITA Medical) Research & Development: $20.19 Mil (TTM As of Mar. 2026)


RCEL AVITA Medical Inc RCEL
66 GF Score
Price $3.95
GF Value $10.78
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AVITA Medical Research & Development?

AVITA Medical RCEL +0.64% 66 Research & Development is $20.19 Mil as of Mar. 2026. GuruFocus rates RCEL with a GF Score™ of 66/100 and a GF Value™ of $10.78 (Possible Value Trap). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. AVITA Medical's Research & Development for the three months ended in Mar. 2026 was $5.63 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $20.19 Mil.

AVITA Medical  (NAS:RCEL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

AVITA Medical Research & Development Related Terms

AVITA Medical Research & Development Historical Data

* Premium members only.

The historical data trend for AVITA Medical's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AVITA Medical Research & Development Chart

AVITA Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.82 13.86 20.82 20.36 20.84

AVITA Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.28 5.12 3.75 5.69 5.63
RCEL
66GF Score
AVITA Medical Inc RCEL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AVITA Medical Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $20.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $20.19 Mil mean?
AVITA Medical (RCEL) has a Research & Development of $20.19 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on AVITA Medical and its competitors.
Is AVITA Medical's Research & Development too high?
AVITA Medical's current Research & Development is $20.19 Mil. Overall, AVITA Medical has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AVITA Medical's Research & Development compare to NNOX and MXCT?
AVITA Medical's Research & Development of $20.19 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on AVITA Medical and its competitors. AVITA Medical's current Research & Development is $20.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AVITA Medical stock overvalued right now?
Based on GuruFocus' analysis, AVITA Medical (RCEL) is currently considered Possible Value Trap. The stock's GF Value™ is $10.78, compared to a current price of $3.95 — trading 63.4% below its estimated fair value. The current Research & Development is $20.19 Mil. AVITA Medical's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For AVITA Medical (RCEL), the current Research & Development is $20.19 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AVITA Medical (RCEL) Overvalued in 2026?

Based on GuruFocus' analysis, AVITA Medical stock appears to be undervalued. The current stock price of $3.95 is trading 63.4% below its estimated GF Value™ of $10.78. GuruFocus considers AVITA Medical to be Possible Value Trap.

Key valuation signals for RCEL:

  • Research & Development: $20.19 Mil
  • GF Value™: $10.78 vs. price of $3.95 (63.4% below fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the RCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AVITA Medical Business Description

Address 28159 Avenue Stanford, Suite 220, Valencia, Santa Clarita, CA, USA, 91355
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
66GF Score

Get the complete analysis for RCEL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.95
Price
$10.78
GF Value